Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT03934372 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Accelerated Phase Chronic Myeloid Leukemia
Blast Phase Chronic Myeloid Leukemia
Chronic Phase Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Acute Lymphocytic Leukemia
Leukemia
Lymphoma
Solid Tumors

Interventions

DRUG: Ponatinib

Sponsor

Incyte Biosciences International Sàrl